Search Within

Myeloma

Formats
  1. Meeting Abstract (556)
  2. Journal Article (360)
  3. Review (36)
  4. Research Letter (21)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (1005)
  2. Department of Medicine (1005)
  3. Hematologic Malignancies, Division of (1005)
  4. Hematologic Malignancies Research (663)
  5. Survivorship Research (369)
  6. Bone Marrow Transplant (300)

More Groups

People
  1. Alexander Lesokhin (375)
  2. Carl Landgren (336)
  3. Hani Hassoun (335)
  4. Sham Mailankody (293)
  5. Malin Hultcrantz (268)
  6. Heather Landau (246)

More People

Years
  1. 2025 (17)
  2. 2024 (82)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (316)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (23)

More Publications

Publishers
  1. American Society of Hematology (338)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (84)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (1005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot plant based dietary intervention in MGUS and SMM is feasible and associated with reduction in insulin and leptin levels
    Meeting Abstract

    Shah, U.; Castro, F.; Anuraj, A.; Blaslov, J.; Adintori, P.; Derkach, A.; Pollak, M.; Maclachlan, K.; Mailankody, S.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone +/- daratumumab induction regimen
    Meeting Abstract

    Meseha, M.; Abusamra, M.; Farooki, A.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Shah, U.; Lu, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker for multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Lu, S.; Patel, D.; Shah, U.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • African American patients with smoldering multiple myeloma may have a lower risk of progression compared to white patients
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Lu, S.; Patel, D.; Shah, U.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: A retrospective study of 34 patients highlighting the need for consensus criteria
    Meeting Abstract

    Pianko, M. J.; Tiutan, T.; Derkach, A.; Jaffer-Sathick, I.; Rossi, A.; Salvatore, S.; Landau, H.; Lahoud, O.; Korde, N.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Cevostamab is efficacious and well tolerated in patients aged < 65 and ≥65 years with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Krishnan, A.; Cohen, A.; Trudel, S.; Spencer, A.; Lesokhin, A.; Wong, C.; Choeurng, V.; Cooper, J.; Sumiyoshi, T.; Goodman, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Maintenance therapy cessation for patients with three-year sustained MRD negative remissions: Initial results from a phase II study
    Meeting Abstract

    Korde, N.; Diamond, B.; Burge, M.; Hassoun, H.; Landau, H.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Shah, U.; Maclachlan, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Clinical and translational results of the myeloma developing regimens using genomics (MyDRUG) sub-protocol C1 targeting RAS mutations
    Meeting Abstract

    Kumar, S.; Jayasinghe, R.; Bianchi, G.; Biran, N.; Hultcrantz, M.; Richter, J.; Vij, R.; Ye, C.; Zonder, J.; DeLello, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Chemotherapy signatures reveal the evolutionary history of post-melphalan myeloid neoplasm
    Meeting Abstract

    Diamond, B.; Ziccheddu, B.; Maclachlan, K.; Taylor, J.; Boyle, E.; Coffey, D.; Lu, S.; Bolli, N.; Bolton, K.; Park, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Microbial changes in response to a plant-based diet and/or supplements in SMM patients: A national multi-arm randomized prospective telehealth study via HealthTree: The nutrition prevention (NUTRIVENTION-2) study
    Meeting Abstract

    Castro, F.; Sweeney, N. W.; Derkach, A.; Traore, K.; Anuraj, A.; Guttentag, L.; Blaslov, J.; Sahagun, A.; Hydren, J.; Chmielewski, C.; more...
    Blood (2022)

    Fulltext@MSK | Save